Risk factors for cytomegalovirus reactivation in patients with kidney disease under immunosuppressive therapy

• Published in: Clinical and experimental nephrology 2022-01, Vol.26 (1), p.22-28
• Main Authors: Iwatani, Yosuke, Amemiya, Nobuyuki, Nokiba, Hirohiko, Yamazaki, Mayuko, Sugiura, Hidekazu, Nitta, Kosaku
• Format: Article
• Language: English
• Subjects: Antigenemia; Antineutrophil cytoplasmic antibodies; Autoantibodies; Cell number; Cytomegalovirus; Glomerulonephritis; Glucocorticoids; Hemodialysis; Hemoglobin; IgA nephropathy; Immunoglobulin A; Immunosuppression; Immunosuppressive agents; Kidney diseases; Leukocytes (neutrophilic); Lymphocytes; Medicine; Medicine & Public Health; Membranous nephropathy; Multivariate analysis; Nephritis; Nephrology; Original Article; Patients; Risk factors; Urology
• ISSN: 1342-1751; 1437-7799
• DOI: 10.1007/s10157-021-02117-5

Background Cytomegalovirus (CMV) is a herpes virus that causes latent infections, and its reactivation due to immunosuppression can cause fatal complications. CMV reactivation is a complication frequently occurring in patients with kidney disease who require immunosuppressive therapy, and, therefore, this study retrospectively examined its risk factors. Methods Patients who received immunosuppressive therapy and underwent the CMV antigenemia test (CMV antigenemia: C7-HRP) for the treatment of primary nephritis (minimal change disease, membranous nephropathy, membranoproliferative glomerulonephritis, focal glomerulosclerosis, and IgA nephropathy) and anti-neutrophil cytoplasmic autoantibody (ANCA)-associated nephritis diagnosed at Saiseikai Kurihashi Hospital from January 2014 to December 2019 were recruited as study participants. Risk factors of CMV reactivation were examined using univariable and multivariable analyses. Results Among the 64 patients (36 men and 28 women; median age, 72 years) included, 34 had primary nephritis (20 minimal disease changes, 10 membranous nephropathy, 1 membranoproliferative glomerulonephritis, 1 focal glomerulosclerosis, and 2 IgA nephropathy) and 30 had ANCA-associated nephritis. Regarding glucocorticoid (GC), 43 patients received oral GC therapy, whereas 21 received GC pulse therapy. CMV reactivation participants showed significant differences in age, ANCA-associated nephritis, hemoglobin level, lymphocyte count, maximum GC dosage, and hemodialysis in univariable analysis. Multivariate analysis showed significantly lower lymphocyte counts in CMV-reactivated patients, but no significant difference in other factors. Conclusion In patients with kidney disease, who require immunosuppressive therapy, CMV reactivation risk is high in patients with low lymphocyte count, and monitoring CMV during the treatment course could lead to early diagnosis and treatment of CMV disease.